|
Jul 10
|
IGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict Alzheimer's Risk and Accelerate Early Detection
|
|
Jun 30
|
IGC Pharma: Fiscal Year 2025 Financial and Operational Highlights - A Year of Transformative Progress in Alzheimer's Innovation
|
|
Jun 27
|
IGC Pharma, Inc. (IGC) Reports Q4 Loss, Beats Revenue Estimates
|
|
Jun 27
|
IGC Pharma to Host Fiscal Year-End 2025 Shareholder Update Call on Monday June 30, 2025
|
|
Apr 24
|
IGC Pharma Welcomes Strategic Investment from Advisors
|
|
Apr 21
|
IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporting Alzheimer's Innovation and AI-Driven Programs
|
|
Apr 1
|
IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health
|
|
Feb 21
|
IGC Pharma expands Holiby line with ‘Longevity’, ‘Renew’
|
|
Feb 20
|
IGC Pharma Expands Holiby(TM) Product Line With 'Longevity' and 'Renew' - Targeting the Multi-Billion-Dollar Anti-Aging Market
|
|
Feb 18
|
IGC Pharma Reports Third Quarter Fiscal 2025 Results
|
|
Feb 11
|
IGC Pharma Expands Into $75 Billion Wellness Market with the Launch of Holiby(TM)
|
|
Oct 17
|
IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1
|
|
Aug 26
|
IGC Announces Results of its 2024 Annual Stockholders Meeting
|
|
Jun 25
|
IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease
|
|
Jun 24
|
IGC Reports Financial Results for Fiscal Year Ended March 31, 2024
|
|
Jun 18
|
IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets
|
|
Apr 16
|
IGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week Two
|
|
Apr 9
|
IGC Pharma Adds Advisor in Artificial Intelligence
|
|
Mar 26
|
IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock
|
|
Mar 20
|
IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation
|